Condition: Advanced Solid Tumors · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This is a multicenter phase II study designed to evaluate the efficacy and safety of TQB3454 as monotherapy in patients with advanced solid tumors, divided into three cohorts.Cohort 1: Enrolled patients with diffuse glioma harbouring IDH1 R132 mutations. Cohort 2: Enrolled patients with advanced solid tumours (excluding glioma) harbouring IDH1 R132 mutations who failed standard therapy. Cohort 3: Enrolled patients with locally advanced, recurrent and/or metastatic biliary tract cancer without IDH1 mutations who progressed after gemcitabine or fluoropyrimidine-based treatment.
This description comes directly from the study's public registry record.
Wenbin Li, Doctor · 15301377998 · neure55@126.com
Jiayong Liu, Doctor · 13641103227 · liujiayong@aliyun.com
Always discuss trial participation with your own doctor first.
| Sanbo Brain Hospital,Capital Medical University | Beijing, Beijing Municipality, China | — |
| Xuanwu Hospital Capital Medical University | Beijing, Beijing Municipality, China | — |
| Beijing Tiantan Hospital, Capital Medical University | Beijing, Beijing Municipality, China | — |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | — |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | — |
| The Second Hospital & Clinical Medical School, Lanzhou University | Lanzhou, Gansu, China | — |
| Sun Yat-Sen Uuniversity Cancer Cerntr | Guangzhou, Guangdong, China | — |
| AnYang Tumor Hospital | Anyang, Henan, China | — |
| Luoyang Central Hospital (Zhengzhou University Affiliated Luoyang Central Hospital) | Luoyang, Henan, China | — |
| Henan Cancer Hospital | Zhengzhou, Henan, China | — |
| Zhengzhou University First Affiliated Hospital | Zhengzhou, Henan, China | — |
| Jiangsu Provincial People's Hospital | Nanjing, Jiangsu, China | — |
+ 10 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07738679